Vanda Pharmaceuticals Inc.

Form 4

February 20, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005 Estimated average

OMB APPROVAL

Form 4 or Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

burden hours per response... 0.5

See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person ** Kelly James Patrick			2. Issuer Name a Symbol	nd Ticker or Trading	5. Relationship of Reporting Person(s) to Issuer			
				ceuticals Inc. [VNDA]	(Check a	ll applicable)		
(Last)	(First)	(Middle)	3. Date of Earliest	Transaction				
			(Month/Day/Year)			10% Owner		
2200 PENNSYLVANIA			02/18/2014		_X_ Officer (give titl			
AVENUE,	SUITE 300E				below) SVP, CFO,	below) Sec & Treasurer		
	(Street)		4. If Amendment,	Date Original	6. Individual or Joint	/Group Filing(Check		
WA CHING	TON DC 200	27	Filed(Month/Day/Y	ear)	Applicable Line) _X_ Form filed by One Form filed by More	1 0		
WASHING	TON, DC 200	13 /			Person	1		
(City)	(State)	(Zip)	Table I - Nor	a-Derivative Securities Acq	uired, Disposed of, o	r Beneficially Owned		
1.Title of	2. Transaction 1	Date 2A. Deei	med 3.	4. Securities Acquired	5. Amount of 6	. 7. Nature		

(City)	(State)	Tabl	e I - Non-L	Derivative	Secur	ities Acqu	iired, Disposed of	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	saction Date 2A. Deemed (Day/Year) Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	
Common Stock	02/18/2014		M	12,500	A	<u>(1)</u>	41,316	D	
Common Stock	02/18/2014		M	4,688	A	(1)	46,004	D	
Common Stock	02/18/2014		M	2,343	A	<u>(1)</u>	48,347	D	
Common Stock	02/18/2014		F	7,124 (2)	D	\$ 13.46	41,223	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> De Se (In

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	TransactionDerivative Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock Unit	<u>(1)</u>	02/18/2014		M	12,500	(3)	<u>(4)</u>	Common Stock	12,500	
Restricted Stock Units	(1)	02/18/2014		M	4,688	<u>(5)</u>	<u>(4)</u>	Common Stock	4,688	
Restricted Stock Units	(1)	02/18/2014		M	2,343	<u>(6)</u>	<u>(4)</u>	Common Stock	2,343	

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		

Director Officer 10% Owner

Kelly James Patrick

2200 PENNSYLVANIA AVENUE

SUITE 300E

WASHINGTON, DC 20037

SVP, CFO, Sec & Treasurer

Signatures

/s/ James Patrick 02/20/2014 Kelly **Signature of Date Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock.

Reporting Owners 2

Edgar Filing: Vanda Pharmaceuticals Inc. - Form 4

- (2) Represents shares of the Issuer's common stock withheld to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4.
- The RSUs vest in four equal annual installments beginning January 1, 2012, provided Mr. Kelly has remained in continuous service with (3) the Issuer on each applicable vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- (4) Not applicable.
- The RSUs vest in four equal annual installments beginning January 1, 2013, provided Mr. Kelly has remained in continuous service with (5) the Issuer on each applicable vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU)
- (5) the Issuer on each applicable vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- 50% of the original RSU award vested on July 29, 2013 due to a milestone achievement, the remaining RSUs vest in four equal annual installments beginning January 1, 2014, provided Mr. Kelly has remained in continuous service with the Issuer on each applicable vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.